Skip to main content
. 2017 Jan 3;8(8):12764–12774. doi: 10.18632/oncotarget.14463

Figure 2. HHT and ibrutinib inhibit the growth of primary AML cells.

Figure 2

FLT3-ITD + primary AML cells (A–D) and FLT3-ITD wt primary AML cells (E–G) were treated with HHT, ibrutinib and HHT+ibrutinib for 24 h. The rate of cell viability was measured by an MTT assay. The CI at the ED50, ED75 and ED90 were presented (H).